Protheragen-ING
12 News & Press Releases found

Protheragen-ING news

Protheragen-ING, a distinguished name in the realm of pharmaceutical innovation, has proudly announced its most sought-after Active Pharmaceutical Ingredients (APIs). Known for offering tailored technical research and development services to researchers globally, Protheragen-ING emphasizes its commitment to pioneering advancement in pharmaceutical sciences. Among the top APIs highlighted are Trilostane, Semaglutid

Mar. 13, 2025

In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination of machine learning algorithms, advanced comput

Feb. 17, 2025

In the world of pharmaceutical ingredients, quality and efficacy has never been more important. To address this need, Protheragen-ING continues to prove itself as a top supplier of nonsteroidal anti-inflammatory APIs (NSAIDs), a class of anti-inflammatory APIs. These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, tooth

Feb. 17, 2025

In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. With cutting-edge solutions in the field of microneedle technology, Protheragen-ING is on the front lines in this field. As a certified ISO9001 supplier of pharmaceutical ingredients and specialty chemicals, Protheragen-ING keeps innovating to meet the latest market demand.

 

Utilizing micron-sized needles

Jan. 18, 2025

This year Protheragen-ING has extended its portfolio of Active Pharmaceutical Ingredients (APIs) to include several hundred new varieties, catering to a broad spectrum of therapeutic needs such as anti-tumor, hypoglycemic, antipsychotic, bronchiectasis, and antihypertensive treatments. Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of p

Dec. 19, 2024